Clinical Trials
0
0 active
Approvals
280
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- Sagent Pharmaceuticals has entered the $200 million U.S. diagnostic dye market through a strategic partnership with Provepharm to commercialize Bludigo, the first and only FDA-approved injectable indigo carmine diagnostic dye. - The collaboration marks Sagent's expansion into the urology space, with Bludigo serving as a visualization aid for cystoscopic evaluation of ureter integrity in adults following urological and gynecological procedures. - Provepharm is repositioning its business model to focus on innovative surgical dyes, particularly fluorescence-guided surgery solutions, with plans to launch two additional diagnostic dyes as early as 2026. - The medical dye solutions market represents more than eight million units per year, driven by increasing complex surgical procedures and the growing adoption of fluorescence-guided surgery in hospital settings.
- Sagent Pharmaceuticals launched travoprost ophthalmic solution USP 0.004% for treating elevated intraocular pressure in open-angle glaucoma and ocular hypertension patients. - The launch marks Sagent's strategic entry into the ophthalmic market, representing a $61 million market opportunity for travoprost specifically. - The company plans to expand its ophthalmic portfolio with additional products in the coming year, targeting the $8.6 billion total addressable ophthalmic market. - This represents Sagent's first ophthalmic product addition to its existing portfolio of over 100 injectable and specialty pharmaceutical products.
